Merrimack Pharmaceuticals (MACK) : Zacks Investment Research ranks Merrimack Pharmaceuticals (MACK) as 4, which is a Sell recommendation. 1 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 2 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 3 research analysts is 2.33, which indicates as a Buy.
Merrimack Pharmaceuticals (MACK) : 2 investment research analysts covering Merrimack Pharmaceuticals (MACK) have an average price target of $11.5 for the near short term. The highest target price given by the Brokerage Firm to the stock is $16 and the lowest target is $7 for the short term. Analysts expect the variance to be within $6.36 of the average price.
Shares of Merrimack Pharmaceuticals, Inc. appreciated by 3.33% during the last five trading days but lost 4.36% on a 4-week basis. Merrimack Pharmaceuticals, Inc. has dropped 23.84% during the last 3-month period . Year-to-Date the stock performance stands at -33.29%. Merrimack Pharmaceuticals (NASDAQ:MACK): stock turned positive on Tuesday. Though the stock opened at $5.16, the bulls momentum made the stock top out at $5.27 level for the day. The stock recorded a low of $5.15 and closed the trading day at $5.27, in the green by 2.53%. The total traded volume for the day was 1,197,012. The stock had closed at $5.14 in the previous days trading.
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company discovering, developing and preparing to commercialize medicines consisting of therapeutics paired with companion diagnostics for the treatment of cancer. The Company has six targeted therapeutic oncology candidates in clinical development (MM-398, MM-302, MM-121, MM-111, MM-151 and MM-141). The Companys most advanced program is its investigational agent MM-398. The Company also has multiple product candidates in preclinical development and a discovery effort advancing additional candidate medicines. The Company has an agreement to utilize its manufacturing know-how to develop, manufacture and exclusively supply bulk drug to a third party, who processes the drug into a finished product and commercializes it globally. The Company is also developing in vitro and in vivo companion diagnostics for use with each of its oncology therapeutic product candidates.